Skip to content
Teethgrinder – Lifestyle
Author:
BridgeBio Pharma, Inc.
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 3, 2026
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 2, 2026
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 1, 2026
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
1
2
3
Next Page
→